We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PhRMA unveiled new criteria for membership, setting higher R&D requirements — and eliminating its associate member level entirely, which included 15 pharmaceutical companies. Read More
The FDA published draft revisions to its blueprint for educating health care providers about extended-release and long-acting opioid painkillers. Read More
Biosimilars consistently drive down average drug prices in markets where they are introduced, according to a report ordered by the European Commission. Read More
Merck Sharp & Dohme Corp. is settling its challenge over a Genentech patent on methods for artificially synthesizing antibodies, a process used for a variety of specialty medicines and cancer therapies. Read More
In yet another pressure point on generic drug prices, a class action suit filed in a Pennsylvania federal court claims Actavis, Teva, Sandoz, Fougera and Taro conspired to fix the prices of fluocinonide creams and gels. Read More
A federal judge ruled that three generics manufacturers infringed on Novartis’ patents related to its Zortress treatment, used during kidney and liver transplants. Read More
Four major patents for Acorda Therapeutics’ successful MS treatment Ampyra were invalidated by a federal judge nearly a decade before they were set to expire — not a month after they were upheld by the PTO. Read More
In a lawsuit filed Monday, Sanofi says Mylan’s anticompetitive business practices blocked its EpiPen competitor, the Auvi-Q, from gaining a foothold in the epinephrine auto-injector market, resulting in hundreds of millions in lost sales. Read More
A California prosecutor is suing Boehringer Ingelheim and a Teva subsidiary, saying their $120 million agreement to push back the release of a generic Aggrenox blood thinner illegally delayed market competition for over seven years. Read More